Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine (Vidaza) combined with Epoetin beta (NeoRecormon) in low-risk and intermediate-1 MDS patients resistant to ESA
2008-004541-29Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Aug 2008
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and epoetin beta in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Major erythroid response rate after 6 courses, Major and minor erythroid response rates after 4 courses and 1 more. Started Aug 2008; status: completed.
02
Drugs
azacitidineepoetin beta
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-004541-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004541-29.